Results 41 to 50 of about 2,198 (193)
Kinome reprogramming is a targetable vulnerability in ESR1 fusion-driven breast cancer [PDF]
, 2023 UNLABELLED: Transcriptionally active ESR1 fusions (ESR1-TAF) are a potent cause of breast cancer endocrine therapy (ET) resistance. ESR1-TAFs are not directly druggable because the C-terminal estrogen/anti-estrogen-binding domain is replaced with ...
et al.,, Gou, Xuxu, Li, Shunqiang
core +2 more sources
Difficulties on the acces to innovative targeted therapies for lung cancer in Spain [PDF]
, 2023 Purpose Spanish Lung Cancer Group (SLCG) conducted a review to analyze the barriers to access to innovative targeted therapies for non-small cell lung cancer (NSCLC) in clinical practice in Spain. Methods Review all relevant content published on websites
Calvo, Virginia +15 more
core +2 more sources
Ret Signaling Pathway and Ret Inhibitors in Human Cancer [PDF]
, 2022 Rearranged during transfection (RET) receptor tyrosine kinase was first identified over thirty years ago as a novel transforming gene. Since its discovery and subsequent pathway characterization, RET alterations have been identified in numerous cancer ...
Lo, Hui-Wen +2 more
core +3 more sources
Treatment of non-small cell lung cancer with RET rearrangements. [PDF]
CancerAbstract Aberrant activation of the RET oncogene by mutations or gene fusions drives various malignancies, including 1%–2% of all non–small cell lung cancers (NSCLCs) that harbor RET gene fusions. Initial attempts to target RET fusion–positive NSCLC with poorly selective multikinase RET inhibitors were associated with significant toxicities and limited
Hoe HJ, Solomon BJ.
europepmc +2 more sources
JTO Clinical and Research Reports, 2023 Selpercatinib and pralsetinib are RET inhibitors with substantial activity in advanced RET-rearranged NSCLC. We present a case of pralsetinib-related pneumonitis and leptomeningeal and brain metastases progression during treatment suspension for ...
Paolo D. d'Arienzo, MD, MRCP +5 more
doaj +1 more source
The Evolving Treatment Landscape of Medullary Thyroid Cancer [PDF]
, 2023 Genetic assessment is crucial to address the correct treatment for advanced medullary thyroid cancer (MTC). Multi tyrosine kinase inhibitors (mTKIs) cabozantinib and vandetanib are good first line options, even vandetanib prescription is currently ...
Alberti, Andrea +5 more
core +1 more source
State of the art and future directions in the systemic treatment of medullary thyroid cancer [PDF]
, 2021 PURPOSE OF REVIEW: Systemic treatment is the only therapeutic option for patients with progressive, metastatic medullary thyroid cancer (MTC). Since the discovery of the rearranged during transfection (RET) proto-oncogene (100% hereditary, 60-90 ...
Broekman, K Esther +3 more
core +1 more source
The importance of the RET gene in thyroid cancer and therapeutic implications [PDF]
, 2021 Since the discovery of the RET receptor tyrosine kinase in 1985, alterations of this protein have been found in diverse thyroid cancer subtypes. RET gene rearrangements are observed in papillary thyroid carcinoma, which result in RET fusion products.
Salvatore D. +2 more
core +1 more source
Frontiers in Oncology, 2022 The identification of receptor-tyrosine kinase gene (RET) fusions in lung cancer has become crucial owing to actionable events that predict responsiveness to tyrosine kinase inhibitors (TKIs).
Sha-Sha Wang +7 more
doaj +1 more source
Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis [PDF]
, 2022 がんゲノム医療のさらなる拡大へ向けた一歩 --コンピュータ解析で意義不明変異のなかに治療標的となる新たな遺伝子変異を発見--. 京都大学プレスリリース. 2022-09-29.Distinguishing oncogenic mutations from variants of unknown significance (VUS) is critical for precision cancer medicine.
Araki, Mitsugu +17 more
core +2 more sources